Carcinoid syndrome

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search
Carcinoid syndrome
Classification and external resources
ICD-10 E34.0
ICD-9 259.2
ICD-O: M8240/3-8245
DiseasesDB 2040
MedlinePlus 000347
eMedicine med/271 
MeSH D008303

WikiDoc Resources for

Carcinoid syndrome

Articles

Most recent articles on Carcinoid syndrome

Most cited articles on Carcinoid syndrome

Review articles on Carcinoid syndrome

Articles on Carcinoid syndrome in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Carcinoid syndrome

Images of Carcinoid syndrome

Photos of Carcinoid syndrome

Podcasts & MP3s on Carcinoid syndrome

Videos on Carcinoid syndrome

Evidence Based Medicine

Cochrane Collaboration on Carcinoid syndrome

Bandolier on Carcinoid syndrome

TRIP on Carcinoid syndrome

Clinical Trials

Ongoing Trials on Carcinoid syndrome at Clinical Trials.gov

Trial results on Carcinoid syndrome

Clinical Trials on Carcinoid syndrome at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Carcinoid syndrome

NICE Guidance on Carcinoid syndrome

NHS PRODIGY Guidance

FDA on Carcinoid syndrome

CDC on Carcinoid syndrome

Books

Books on Carcinoid syndrome

News

Carcinoid syndrome in the news

Be alerted to news on Carcinoid syndrome

News trends on Carcinoid syndrome

Commentary

Blogs on Carcinoid syndrome

Definitions

Definitions of Carcinoid syndrome

Patient Resources / Community

Patient resources on Carcinoid syndrome

Discussion groups on Carcinoid syndrome

Patient Handouts on Carcinoid syndrome

Directions to Hospitals Treating Carcinoid syndrome

Risk calculators and risk factors for Carcinoid syndrome

Healthcare Provider Resources

Symptoms of Carcinoid syndrome

Causes & Risk Factors for Carcinoid syndrome

Diagnostic studies for Carcinoid syndrome

Treatment of Carcinoid syndrome

Continuing Medical Education (CME)

CME Programs on Carcinoid syndrome

International

Carcinoid syndrome en Espanol

Carcinoid syndrome en Francais

Businness

Carcinoid syndrome in the Marketplace

Patents on Carcinoid syndrome

Experimental / Informatics

List of terms related to Carcinoid syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Carcinoid syndrome refers to the array of symptoms that occur secondary to carcinoid tumors. Carcinoid tumors are discrete, yellow, well-circumscribed tumors that can occur anywhere along the gastrointestinal tract (GI). They most commonly affect the appendix, ileum, and rectum. These tumors are unique in that they are endocrine in nature. They secrete hormones into the blood stream, which then travel to end organs and act upon them via appropriate receptors. Although quite rare, 15 cases/1,000,000 population, carcinoid tumors account for 75% of GI endocrine tumors.

Clinical presentation

Clinical findings include:[1]

  • Flushing of the skin
  • Diarrhea and abdominal cramps
  • Right sided heart disease
  • bronchoconstriction
  • abdominal pain due to desmoplastic reaction of the mesentery
  • in most patients, increased urinary excretion of 5-HIAA (5-hydroxyindoleacetic acid), a degradation product of serotonin
  • Serotonin causes fibrosis of the tricuspid valve and pulmonary valve
    • "TIPS" - Tricuspid Insufficiency, Pulmonic Stenosis (fibrosis of tricuspid and pulmonary valves)

Pathophysiology

Carcinoid tumors produce the vasoactive substance, serotonin; it is commonly but incorrectly thought that serotonin is the cause of the flushing. The flushing results from secretion of kallikrein, the enzyme that catalyzes the conversion of kininogen to lysyl-bradykinin. The latter is further converted to bradykinin, one of the most powerful vasodilators known. Other components of the carcinoid syndrome are diarrhea (probably caused by serotonin), a pellagra-like syndrome (probably caused by diversion of large amounts of tryptophan from synthesis of the vitamin, niacin, to the synthesis of 5-hydroxyindoles including serotonin), fibrotic lesions of the endocardium, particularly on the right side of the heart resulting in insufficiency of the tricuspid valve and, less frequently, the pulmonary valve and, uncommonly, bronchoconstriction. The pathogenesis of the cardiac lesions and the bronchoconstriction is unknown. When the primary tumor is in the gastrointestinal tract, as it is in the great majority of cases, the serotonin and kallikrein are inactivated in the liver; manifestations of carcinoid syndrome do not occur until there are metastases to the liver. Carcinoid tumors arising in the bronchi, because their biologically active products reach the systemic circulation before passing through the liver, may be associated with manifestations of carcinoid syndrome without liver metastases.

Diagnosis

With a certain degree of clinical suspicion, diagnosis is made primarily by measuring plasma levels of the secreted glycoprotein Chromogranin A, supported by measuring the 24 hour urine levels of 5-HIAA (5-hydroxyindoleacetic acid), a breakdown product of serotonin. Patients with carcinoid syndrome usually excrete >25 mg of 5-HIAA per day. For localization of both primary lesions and metastasis, the initial imaging method is Octreoscan, where 111Indium labelled somatostatin analogues (octreotide) are used in scintigraphy for detecting tumors expressing somatostatin receptors. Median detection rates with octreoscan are about 89%, in contrast to other imaging techniques such as CT scans and MRI with detection rates of about 80%. Usually on CT scan, one will note a spider-like/crab like change in the messentery due to the fibrosis from the release of serotonin. PET scans, which evaluate for increased metabolism of glucose, may also aid in localizing the carcinoid lesion or evaluating for metastases.

Localization of tumour

Tumour localization may be extremely difficult , Barium swallow and follow-up examination of the intestine may occasionally show the tumour. Capsule video endoscopy has recently been used to localized the tumour. Often laparotomy is the definitive way to localize the tumour.

Treatment

For symptomatic relief of carcinoid sydrome:

  • Octreotide (somatostatin analogue- neutralizes serotonin and decreases urinary 5-HIAA)
  • Methysergide maleate (antiserotonin agent but not used because of serious side effect of retroperitoneal fibrosis)
  • Cyproheptadine (antihistamine)

Alternative treatment for qualifying candidates:

Prognosis

Prognosis varies from individual to individual. It ranges from a 95% 5 year survival for localized disease to a 20% 5 year survival for those with liver metastases. The average survival time from the start of octreotide treatment has increased to about 12 years.

Synonyms

Thorson-Bioerck syndrome, argentaffinoma syndrome, Cassidy-Scholte sydrome, flush syndrome

References

  1. "Endocrine Tumors of the GI Tract and Pancreas." Harrison's Manual of Medicine. Eugene Braunwald. 15th edition. New York: McGraw-Hill, 2002. 298-299.
  2. "Malignant Carcinoid Syndrome." Current Medical Diagnosis & Treatment. Lawrence M. Tierney, Jr. 43rd edition. New York: Lange Medical Books/McGraw-Hill, 2004. 1625.
  3. "Carcinoid Syndrome." Griffith's 5 Minute Clinical Consult. Mark Dambro. Mobile Version 6.0.139. Lippincott, Williams and Wilkins, 2003.
  4. "Current Status of Gastrointestinal Carcinoids." Gastroenterology. Irvin M. Modlin et al. 2005;128;1717-1751.

See also

External links and Patient Resources


de:Flush-Syndrom
WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch


Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

Personal tools